Covid-19 roundup: OCD drug shows 31% hos­pi­tal­iza­tion re­duc­tion in plat­form tri­al; EUA for boost­er mR­NA shot im­mi­nent — re­ports

Re­searchers in­ves­ti­gat­ing re­pur­posed ther­a­pies to treat Covid-19 un­veiled a new cut of da­ta last week look­ing at how the SS­RI flu­vox­am­ine can af­fect hos­pi­tal­iza­tions from the dis­ease com­pared to place­bo.

Eval­u­at­ing 1,480 pa­tients as of the Aug. 2 da­ta cut­off, sci­en­tists work­ing on the TO­GETH­ER tri­al ob­served a 31% re­duc­tion in hos­pi­tal­iza­tions or emer­gency room stays last­ing longer than 6 hours in pa­tients with a pos­i­tive Covid-19 test. Re­searchers pre­sent­ed their find­ings on Aug. 6, not­ing there were 74 con­firmed cas­es in the drug arm and 107 in the place­bo group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER